Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 23

Results For "AstraZeneca"

250 News Found

Green chemistry approaches to synthesis could make a big difference to pharma product outputs
News | January 20, 2022

Green chemistry approaches to synthesis could make a big difference to pharma product outputs

Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies


Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer
Biotech | January 19, 2022

Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer

These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium


Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report
News | January 10, 2022

Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma


Bharat Biotech's intranasal vaccine Phase 3 trials gets approval
News | January 05, 2022

Bharat Biotech's intranasal vaccine Phase 3 trials gets approval

It has also been granted permission to conduct trials for booster dose


Green ChemisTree Foundation announces virtual conference on Innovations in Green & Sustainable Chemistry for Pharma Industry
News | December 30, 2021

Green ChemisTree Foundation announces virtual conference on Innovations in Green & Sustainable Chemistry for Pharma Industry

Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness


Trastuzumab deruxtecan type II variation application validated by EMA
Biotech | December 28, 2021

Trastuzumab deruxtecan type II variation application validated by EMA

Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)


Evusheld neutralises Omicron in latest studies
News | December 23, 2021

Evusheld neutralises Omicron in latest studies

Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19


Sputnik Light booster after Sputnik V effective against Omicron: Study
News | December 22, 2021

Sputnik Light booster after Sputnik V effective against Omicron: Study

Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination


Astra Zeneca’s antibody combination to prevent Covid-19 neutralises Omicron variant
News | December 17, 2021

Astra Zeneca’s antibody combination to prevent Covid-19 neutralises Omicron variant

The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research


USFDA authorises Astra’s antibody cocktail to prevent Covid
Drug Approval | December 09, 2021

USFDA authorises Astra’s antibody cocktail to prevent Covid

Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19